Category: Pharmaceuticals
Africa Pharmaceuticals
Research Assistance
-
Cameroon Pharmaceuticals & Healthcare Q3 2018
... rolling out of this health financing mechanism will proceed at a slowpace, however, given the current low level of health system development. More broadly, sustained economic growth bodes well forpharmaceutical spending growth over the medium ... Read More
-
Kenya Pharmaceuticals & Healthcare Q3 2018
... include the commitment to ensure universal healthcare coverage,and the rising disease burden, both in terms of non- and communicable conditions. Additionally, Kenyans are some of the mostprolific users of internet, which bodes well for the ... Read More
-
Angola Pharmaceuticals & Healthcare Report Q3 2018
... demographic, per capita spending on medicines will remainsignificantly low over our forecast period. However, overall growth of the market will be supported by a rapidly growing populationcoupled with small but steady improvements to healthcare access ... Read More
-
Zambia Pharmaceuticals & Healthcare Report Q3 2018
... However, few opportunities exist from the perspective ofmultinational companies, given factors such as the low purchasing power and the wide-spread presence of counterfeit medicines.On the other hand, authorities' support for the reduction of reliance on ... Read More
-
Algeria Pharmaceuticals & Healthcare Report Q3 2018
... years. Algeria’s strategic geographicalposition and government incentives for investors will support the country’s long-term aspiration towards becoming a drugmanufacturing and export base. That said, slow progress in revising drug pricing regulations and import restrictions will ... Read More
-
Gabon Pharmaceuticals & Healthcare Q2 2018
... signal greater commercial potential fordrugmakers, however, exploiting these opportunities will be challenging in nature as the undeveloped status of the country'spharmaceutical and healthcare markets poses a much less receptive environment for drugmaker opportunities in Sub-SaharanAfrica. Read More
-
Mozambique Pharmaceuticals & Healthcare Q2 2018
... significantly low as a result of widespread poverty amongst the population, limiting potential revenue prospects for drugmakers.Furthermore, weak intellectual property standards and a poorly enforced pricing regime make Mozambique a high-risk environmentfor innovative medicine producers. Read More
-
Ghana Pharmaceuticals & Healthcare Q2 2018
... over innovative multinational firms. In order to ensure thepopulation’s healthcare and access to safe medicines are not compromised by such measures, protectionist policies aimed atboosting local drugmaker capabilities must be accompanied by improvements to medical ... Read More
-
Tunisia Pharmaceuticals & Healthcare Q2 2018
... with domesticfirms. Improving healthcare access will be beneficial to the country's pharmaceutical market growth prospects over the comingyears; however, growth will remain limited by the steady uptake of generic drugs in the country. The next ... Read More
-
Namibia Pharmaceuticals & Healthcare Q2 2018
... country's competitiveness in theSouthern Africa region. These factors continue to act as a deterrent to multinational pharmaceutical company investment in thelocal production of medicines. As a result, Namibia is heavily reliant on importing the majority ... Read More
-
Botswana Pharmaceuticals & Healthcare Q2 2018
... diversify the country’s economyand invests in infrastructure. However, although Botswana makes for a relatively attractive manufacturing destination, its smallmarket size will continue to limit foreign drugmaker interest as they instead opt for South Africa as ... Read More
-
Uganda Pharmaceuticals & Healthcare Report Q2 2018
... access tothese essential medicines. While the government recognises the need to improve the situation and is implementing certainstrategies to address this, health sector inefficiencies persist and there is an absence of a sustainable, long-term plan. Read More
-
Tanzania Pharmaceuticals & Healthcare Report Q2 2018
... over the coming years. However, we note that growth will bepartly due to inflationary pressures from a relatively low value base. The demand for high-value drugs will remain limited by itsunderdeveloped healthcare system and low ... Read More
-
Cameroon Pharmaceuticals & Healthcare Report Q2 2018
... implementation phase reach a high level ofsuccess, the UHC scheme has the potential to transform Cameroon's health system while positioning the country among the mostpromising in Sub-Saharan Africa in terms of health sector growth. We ... Read More
-
Middle East And North Africa Pharmaceuticals & Healthcare Report Q2 2018
... urbanization, the region's overwhelming chronic disease burdenwill be an important factor supporting pharmaceutical and healthcare market growth over a multi-year horizon. There is a significantdisparity between different countries' healthcare systems in the MENA region, resulting ... Read More
-
Cote d'Ivoire Pharmaceuticals & Healthcare Report Q2 2018
... of healthcare coverage deter any meaningful investment bymultinational firms. While a positive economic trajectory bodes well for government finances, the focus will remain on the deliveryof basic healthcare services, offering limited opportunities for foreign pharmaceutical ... Read More
-
Morocco Pharmaceuticals & Healthcare Report Q2 2018
... improving healthcare quality and coverage. However, innovative drugmakers willremain deterred by the relatively small scale of the market as well as the low purchasing power of the population. Further downsiderisks include the government's increasing preference ... Read More
-
Nigeria Pharmaceuticals & Healthcare Report Q2 2018
... The majority of multinational players will continue to optfor an indirect presence as the business climate remains decidedly difficult, yet the long-term opportunities will manifest in line witheconomic growth and greater investor sentiment. While opportunities ... Read More
-
Ethiopia Pharmaceuticals & Healthcare Q2 2018
... - a headwind to drugmaker and private sectoropportunities in Ethiopia. The Ethiopian Pharmaceutical Manufacturing Sector Strategy and Action Plan highlights the government'spolitical will to improve policy coherence in the sector, while trying to improve the ... Read More
-
Sudan and South Sudan Pharmaceuticals & Healthcare Report Q2 2018
... relations with the US, the operating environment remains highlychallenging and will continue to restrict company activity. Over the long term, a gradually improving business climate and Sudan'smore favourable position in the International community hold upside ... Read More
-
Vaccine Markets in Africa to 2022
... countries. The package includes country reports from the following countries: Egypt, Ghana, Kenya, Malawi, Morocco, Nigeria, Tanzania The research includes historical data from 2011 to 2017 and forecasts until 2022 which makes the reports an ... Read More
-
Vaccine Market in Nigeria to 2022
... includes historical data from 2011 to 2017 and forecasts until 2022 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry ... Read More
-
Insulin Market in Ghana to 2022
... includes historical data from 2011 to 2017 and forecasts until 2022 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry ... Read More
-
Insulin Market in Malawi to 2022
... includes historical data from 2011 to 2017 and forecasts until 2022 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry ... Read More
-
Insulin Market in Morocco to 2022
... includes historical data from 2011 to 2017 and forecasts until 2022 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry ... Read More
